Approved Hospital Formulary
Add Formweb to your mobile device
Search results for:
morphine
morphine
Brand names: Astramorph PF, AVINza, Duramorph PF, Kadian, Morphine Sulfate, Morphine Sulfate ER, MS Contin, Roxanol
| Form | Strength |
|---|---|
| CAPSULE, EXTENDED RELEASE, ORAL | 10 mg/24 hr; 20 mg/24 hr; 30 mg/24 hours; 45 mg/24 hours; 50 mg/24 hours; 60 mg/24 hours; 90 mg/24 hours; 120 mg/24 hours |
| CONCENTRATE, ORAL | 20 mg/mL |
| SOLUTION, INJECTABLE | 0.5 mg/mL PF; 0.5 mg/mL preservative-free; 1 mg/mL PF; 1 mg/mL preservative-free; 2 mg/mL; 4 mg/mL; 5 mg/mL; 10 mg/mL; 15 mg/mL; 25 mg/mL preservative-free; 50 mg/mL |
| SOLUTION, INTRAVENOUS | 1 mg/mL-NaCl 0.9%; 2 mg/mL-NaCl 0.9% |
| SOLUTION, ORAL | 10 mg/5 mL; 20 mg/5 mL |
| SUPPOSITORY, RECTAL | 10 mg |
| TABLET, EXTENDED RELEASE, ORAL | 15 mg/12 hr; 30 mg/12 hr; 60 mg/12 hours; 100 mg/12 hours; 200 mg/12 hours |
| TABLET, ORAL | 15 mg; 30 mg |
Last updated: Nov. 30, 2021
- High Alert: CAUTION: See High-Alert Medication Policy
- RCRA: Disposal
- RCRA: Management of Pharmaceutical Waste Policy
- Do Not Crush: Enteric Coated/ER Capsule
- Black Box Warning: 24-hour observation following epidural/intrathecal administration
- REMS: Opioid Analgesic REMS
Class II
morphine
Patient Controlled Analgesia (PCA): See Policy 900.4103
Use of oral morphine solution in Neonatal Opioid Withdrawal Syndrome (NOWS): See Protocol 911.5076
Morphine sulphate may be given via hypodermoclysis (HDC/subcutaneous infusion). See Procedure 904.4991
Use in mechanically ventilated patients, See the Pain, Agitation and Delirium Protocol (aka "PAD") Protocol 901.6008
For pediatric long term sedation weaning: See Protocol 912.6016
Administration of concentrated oral 20mg/1ml morphine solution (ROXANOL): See Tip Sheet on Sublingual (SL) Administration
Infusion Concentrations and Ranges:
Adult General Titration Ranges and Administration (weight based dosing): See Handout (updated Aug 2016)